BBOT — BridgeBio Oncology Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1869105 ·
Last close
$1.94
Market Cap
$155.69M
52W High
$14.87
52W Low
$1.93
ADV30
631,593
Next earnings
2026-11-10
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -37,488,000 -34,176,000 346,224,000 76,479,000 52,836,000
Jun 2026 0 — -60,187,000 -56,454,000 376,706,000 54,063,000 53,594,000
Mar 2026 0 — -46,179,000 -42,106,000 417,646,000 52,658,000 45,366,000
Dec 2025 0 — -43,408,000 -38,797,000 448,381,000 373,687,000 37,285,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-150,877,000
Investing CF
$-181,573,000
Financing CF
$188,000
CapEx
$-157,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.15
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-489,303,000
Inventory
—
Receivables
$155,000
ST Investments
$117,390,000
EBIT TTM
$-187,262,000
Pretax Income TTM
$-171,533,000
Interest Exp TTM
—
Analysts
11

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -145,819,000 -134,044,000 448,381,000 37,285,000 411,096,000 -113,894,000
Dec 2024 0 -80,863,000 -74,275,000 164,301,000 342,938,000 -178,637,000 -55,027,000
Dec 2023 0 -64,771,000 -64,699,000 5,942,000 121,583,000 -115,641,000 -52,079,000

TTM Snapshot

Revenues TTM
$-3,604
NetIncome TTM
$-233,034,918
OpCashFlow TTM
—
Assets (Latest)
$376,706,000
Forward EPS
$-2.09

Peers — same industry

TickerNameMarket CapLastDaily %
ABEO ABEONA THERAPEUTICS INC. $160.27M $2.60 —
ANTX AN2 Therapeutics, Inc. $160.50M $4.23 —
BCYC BICYCLE THERAPEUTICS PLC $162.10M $3.20 —
PRQR ProQR Therapeutics N.V. $162.29M $1.15 —
YARW Yarrow Bioscience, Inc. $163.04M $14.21 —

News headlines (Yahoo Finance, 1h cache)

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-10-12 20:05 · Yahoo
BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook
2026-09-12 07:40 · Yahoo
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
2026-09-08 20:05 · Yahoo
BBOT to Participate in Upcoming Investor Healthcare Conferences
2026-09-01 20:05 · Yahoo
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More
2026-05-11 11:58 · Yahoo
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
2026-09-11 09:37 · Yahoo
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
2026-08-11 20:05 · Yahoo
BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
2026-11-10 21:15 · Yahoo
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?
2026-06-30 13:06 · Yahoo
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
2026-05-17 18:18 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.